Search results for " TRIALS"

showing 10 items of 932 documents

Mediterranean Diet and Cardiovascular Health: Teachings of the PREDIMED Study123

2014

The PREDIMED (Prevención con Dieta Mediterránea) study was designed to assess the long-term effects of the Mediterranean diet (MeDiet) without any energy restriction on incident cardiovascular disease (CVD) as a multicenter, randomized, primary prevention trial in individuals at high risk. Participants were randomly assigned to 3 diet groups: 1) MeDiet supplemented with extra-virgin olive oil (EVOO); 2) MeDiet supplemented with nuts; and 3) control diet (advice on a low-fat diet). After 4.8 y, 288 major CVD events occurred in 7447 participants; crude hazard ratios were 0.70 (95% CI: 0.53, 0.91) for the MeDiet + EVOO and 0.70 (95% CI: 0.53, 0.94) for the MeDiet + nuts compared with the contr…

Aged 80 and overMaleMetabolic SyndromeMiddle AgedDiet MediterraneanCardiovascular SystemPrimary PreventionObservational Studies as TopicNutrigenomicsMeta-Analysis as TopicCardiovascular DiseasesHumansNutsPlant OilsFemaleSupplement: 20th International Congress of Nutrition (ICN)Diet Fat-RestrictedOlive OilBiomarkersAgedRandomized Controlled Trials as Topic
researchProduct

Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of…

2019

ObjectiveTo systematically review the effect of oral intake of bacterial probiotics on 15 variables related to obesity, diabetes and non-alcoholic fatty liver disease.DesignSystematic review and meta-analysis.Data sourcesMedline, EMBASE and COCHRANE from 1990 to June 2018.Eligibility criteriaRandomised controlled trials (≥14 days) excluding hypercholesterolaemia, alcoholic liver disease, polycystic ovary syndrome and children <3 years.ResultsOne hundred and five articles met inclusion criteria, representing 6826 subjects. In overweight but not obese subjects, probiotics induced improvements in: body weight (k=25 trials, d=−0.94 kg mean difference, 95% CI −1.17 to −0.70, I²=0.0%), body ma…

Alcoholic liver diseasemedicine.medical_specialtyobesitybifidobacteriumGastroenterology03 medical and health sciences0302 clinical medicineInsulin resistanceDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumans030212 general & internal medicine1506BifidobacteriumRandomized Controlled Trials as Topic2. Zero hunger[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismNutrition and Metabolismbiologydiabetesbusiness.industryProbioticsResearchFatty livernon-alcoholic fatty liver diseaseGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseasebiology.organism_classificationPolycystic ovaryObesity3. Good healthlactobacillus[SDV.AEN] Life Sciences [q-bio]/Food and NutritionTreatment Outcome[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieDietary Supplements[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie1714businessBody mass index[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryBMJ open
researchProduct

Efficacy and safety of allergen immunotherapy in patients with allergy to molds: A systematic review

2018

BACKGROUND Allergen immunotherapy (AIT) with mould extracts has been performed for many years but the final demonstration of its clinical efficacy is still missing, due to the small number of studies and their inconsistent results. OBJECTIVE To systematically review efficacy and safety of AIT for the treatment of respiratory allergies to moulds. DESIGN The primary outcomes were safety and reduction of symptoms (Symptom Score, SS) and medication use (Medication Score, MS) in patients treated with AIT compared to controls. The strength of the evidence was graded based on the risk of bias, consistency and magnitude of effect, according to the GRADE Working Group's guide. DATA SOURCES Medline, …

Allergen immunotherapymedicine.medical_specialtyAllergyAntigens FungalImmunologyMEDLINECochrane LibraryPlacebo03 medical and health sciences0302 clinical medicinePharmacotherapyInternal medicineHypersensitivityHumansImmunology and AllergyMedicineAnti-Asthmatic Agents030212 general & internal medicineAsthmaClinical Trials as Topicbusiness.industryFungiAllergensmedicine.diseasePhenotypeTreatment Outcome030228 respiratory systemDesensitization ImmunologicSample size determinationbusinessClinical & Experimental Allergy
researchProduct

Technical standards in allergen exposure chambers worldwide - an EAACI Task Force Report

2021

Allergen exposure chambers (AECs) can be used for controlled exposure to allergenic and non-allergenic airborne particles in an enclosed environment, in order to (i) characterize the pathological features of respiratory diseases and (ii) contribute to and accelerate the clinical development of pharmacological treatments and allergen immunotherapy for allergic disease of the respiratory tract (such as allergic rhinitis, allergic rhinoconjunctivitis, and allergic asthma). In the guidelines of the European Medicines Agency for the clinical development of products for allergen immunotherapy (AIT), the role of AECs in determining primary endpoints in dose-finding Phase II trials is emphasized. A…

Allergen immunotherapymedicine.medical_specialtyAllergyImmunologytechnical standardsmedicineImmunology and AllergyHumansallergen exposure chambersIntensive care medicineCOVID-19 ; allergen exposure chambers ; clinical trials ; Allergie ; technical standards ; allergen immunotherapyField exposureclinical trialsTask forcebusiness.industryCOVID-19Technical informationAllergic asthmaAllergensrespiratory systemmedicine.diseaseRhinitis AllergicAsthmaClinical trialDesensitization Immunologicallergen immunotherapyPollenALLERGEN EXPOSUREbusiness
researchProduct

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

2015

Accepted Article

AllergyAllergyMedical InformaticSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOWORLD-HEALTH-ORGANIZATIONReviewComorbidityWeb BrowserHealth informatics:Medicina Clínica [Ciências Médicas]ARIA; ICT; MACVIA-LR; allergic rhinitis; asthma; clinical decision support system; conjunctivitis; visual analogue scalevisual analogue scaleQUALITY-OF-LIFEconjunctivitisMedicineImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSRhinitisClinical Trials as TopicCLIMATE-CHANGE[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAllergenHealth PolicyDisease ManagementRANDOMIZED CONTROLLED-TRIAL3. Good healthCHRONIC RESPIRATORY-DISEASESclinical decision support systemINTEGRATED CARE PATHWAYS1107 ImmunologyVISUAL ANALOG SCALESPractice Guidelines as TopicMedical emergencyallergic rhinitiLife Sciences & BiomedicineHumanEUROPEAN INNOVATION PARTNERSHIPImmunologyClinical Decision-MakingSocio-culturaleReproducibility of Resultallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web Browser; Immunology and Allergy; ImmunologyInformation and communications technologyClinical decision support systemMACVIA-LRQuality of life (healthcare)AllergicARIA; Information and communications technology; MACVIA-LR; allergic rhinitis; asthmaJournal ArticleHumansCiências Médicas::Medicina ClínicaAsthmaScience & Technologyallergic rhinitisARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAReproducibility of ResultsGuidelineBiomarkerta3121Allergensasthmamedicine.diseaseRhinitis AllergicIntegrated careHealth PlanningPOLLEN COUNTSICTallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web BrowserImmunologybusinessDECISION-SUPPORT-SYSTEMSBiomarkersMedical Informatics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic…

2020

AbstractThe COVID-19 pandemic has surprised the entire population. The world has had to face an unprecedented pandemic. Only, Spanish flu had similar disastrous consequences. As a result, drastic measures (lockdown) have been adopted worldwide. Healthcare service has been overwhelmed by the extraordinary influx of patients, often requiring high intensity of care. Mortality has been associated with severe comorbidities, including chronic diseases. Patients with frailty were, therefore, the victim of the SARS-COV-2 infection. Allergy and asthma are the most prevalent chronic disorders in children and adolescents, so they need careful attention and, if necessary, an adaptation of their regular…

AllergyReview030207 dermatology & venereal diseasesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineCOVID-19 ; Child ; Pandemic ; Allergy ; Immunologic disease ; Asthma ; AdolescentPandemicViral030212 general & internal medicineDisease management (health)ChildSocieties MedicalCOVID-19; pandemic; child; adolescent; allergy; asthma; immunologic diseaseIncidence (epidemiology)lcsh:RJ1-570Disease ManagementGeneral MedicineAtopic dermatitisSettore MED/38Adolescent; Allergy; Asthma; Child; COVID-19; Immunologic disease; Pandemic; Adolescent; COVID-19; Child; Coronavirus Infections; Decision Making; Humans; Italy; Pneumonia Viral; Pragmatic Clinical Trials as Topic; SARS-CoV-2; Allergy and Immunology; Betacoronavirus; Consensus; Disease Management; Pandemics; Societies MedicalItalyLatex allergyAdolescent; Allergy; Asthma; COVID-19; Child; Immunologic disease; PandemicCoronavirus InfectionsHumanTelemedicineConsensusAdolescentDecision MakingPneumonia ViralConsensuBetacoronavirus03 medical and health sciencesMedicalAllergy and ImmunologyPragmatic Clinical Trials as TopicmedicineHumansRisk factorPandemicsPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2COVID-19lcsh:PediatricsPneumoniamedicine.diseaseAsthmaAdolescent; Allergy; Asthma; Child; COVID-19; Immunologic disease; PandemicImmunologic diseaseImmunologySocietiesbusinessRare disease
researchProduct

Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Aminobisphosphonate Gamma delta T cells cancermedicine.medical_treatmentT cellClinical BiochemistryReceptors Antigen T-CellAntineoplastic AgentsModels BiologicalInterleukin 21Immune systemAntigenT-Lymphocyte SubsetsIn vivoNeoplasmsDrug DiscoveryAnimalsHumansCytotoxic T cellMedicinePharmacologyClinical Trials as TopicDiphosphonatesbusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaImmunotherapyKiller Cells Naturalmedicine.anatomical_structureImmune SystemImmunologyInterleukin-2ImmunotherapybusinessImmunologic MemoryExpert Opinion on Biological Therapy
researchProduct

Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways …

2018

A semi-physiological two compartment pharmacokinetic model with two active metabolites (primary (PM) and secondary metabolites (SM)) with saturable and non-saturable pre-systemic efflux transporter, intestinal and hepatic metabolism has been developed. The aim of this work is to explore in several scenarios which analyte (parent drug or any of the metabolites) is the most sensitive to changes in drug product performance (i.e. differences in in vivo dissolution) and to make recommendations based on the simulations outcome. A total of 128 scenarios (2 Biopharmaceutics Classification System (BCS) drug types, 2 levels of KM Pgp, in 4 metabolic scenarios at 2 dose levels in 4 quality levels of t…

AnalyteCmaxPharmaceutical ScienceAdministration Oral02 engineering and technologyEquivalence Trials as TopicPharmacologyBioequivalence030226 pharmacology & pharmacyModels Biological03 medical and health sciencesFirst pass effect0302 clinical medicinePharmacokineticsHumansComputer SimulationPharmacokineticsIntestinal MucosaBiotransformationChemistryMembrane Transport Proteins021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemNONMEMNonlinear DynamicsPharmaceutical PreparationsSolubilityTherapeutic EquivalencyResearch DesignArea Under CurveLinear Models0210 nano-technologyMonte Carlo MethodDrug metabolismEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Role of ARBs in the blood hypertension therapy and prevention of cardiovascular events

2009

Hypertension has a worldwide high incidence in the general population and undoubtedly it is the most important risk factor for cardiovascular morbidity and mortality, in industrialized countries. In this Review we investigated the role of angiotensin II receptor antagonists (ARBs) therapy in the treatment of essential hypertension. We selected in the PubMed and in a list of selected sources the most significant clinical trials and meta-analysis carried out from 1999 to now, to assess, in adult patients populations, ARBs efficacy, safety and tolerability profile, in comparison with the efficacy of the other common antihypertensive drugs, with particular regard to both the prevention of disab…

Angiotensin receptormedicine.medical_specialtyHeart DiseasesCost-Benefit AnalysisClinical BiochemistryPopulationPeptidyl-Dipeptidase AEssential hypertensionAngiotensin Receptor AntagonistsInternal medicineDrug DiscoverymedicineHumansRisk factoreducationAntihypertensive AgentsPharmacologyeducation.field_of_studyClinical Trials as TopicAngiotensin Receptor Antagonistsbusiness.industrymedicine.diseaseClinical trialCerebrovascular DisordersTreatment OutcomeTolerabilityARB blood hypertension cardiovascular eventsHeart failureHypertensionCardiologyMolecular Medicinebusiness
researchProduct

Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

2008

The extent to which HIV-1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV-1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy-three HIV-1-infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow-up data after a 12-week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was si…

Anti-HIV AgentsDNA Mutational AnalysisMolecular Sequence DataProviral DNAHIV InfectionsHAART failuremedicine.disease_causeDNA Mutational Analysichemistry.chemical_compoundHIV ProteaseProvirusesAntiretroviral Therapy Highly ActiveVirologyDrug Resistance ViralDNA Mutational AnalysismedicineHumansMulticenter Studies as TopicHIV InfectionTreatment FailureGenotypingRandomized Controlled Trials as TopicCOLD-PCRMutationPlasma RNAbiologyProviruseSequence Analysis RNAAnti-HIV AgentRNASequence Analysis DNAbiology.organism_classificationVirologyHIV Reverse TranscriptaseReverse transcriptaseAntiretroviral genotypic resistanceInfectious DiseaseschemistryDNA ViralMutationLentivirusImmunologyHIV-1RNA ViralDNAantiretroviral genotypic resistance; haart failure; hiv-1; plasma rna; proviral dnaHumanJournal of Medical Virology
researchProduct